HSN: 76

NAME: FURAN

CAS-RN: 110-00-9

DATE: 20180416

Risk Values - Summary Table

Summary Risk Table for:FURAN
Risk Value Parameter OrganizationATSDRHealth CanadaIARCIPCSIPRVITER PRNSF IntlRIVMTCEQU.S.EPA
Oral: Non-Cancer
--
--
--
--
--
--
--
--
--
green check
Oral: Cancer
--
--
green check
--
--
--
--
--
--
--
Inhalation: Non-Cancer
--
--
--
--
--
--
--
--
--
--
Inhalation: Cancer
--
--
green check
--
--
--
--
--
--
--
green check = Chemical evaluated and ITER data online.


Noncancer Oral Risk Values Table:

ITER Noncancer Oral Risk Table for: FURAN
Risk Value Parameter OrganizationATSDRHealth CanadaIARCIPCSIPRVITER PRNSF IntlRIVMTCEQU.S.EPA
Risk Value Name
--
--
--
--
--
--
--
--
--
RfD
Risk Value*
--
--
--
--
--
--
--
--
--
1E-3
Year
--
--
--
--
--
--
--
--
--
1987
Base(Experimental)*
--
--
--
--
--
--
--
--
--
NOAEL 2
Basis(Adjusted)*
--
--
--
--
--
--
--
--
--
1.4
Uncertainty Factor
--
--
--
--
--
--
--
--
--
1000
Critical Organ or Effect
--
--
--
--
--
--
--
--
--
liver
Species
--
--
--
--
--
--
--
--
--
mouse
Study
--
--
--
--
--
--
--
--
--
NTP, 1982
Biomonitoring Blood
--
--
--
--
--
--
--
--
--
4E-02
Biomonitoring Urine
--
--
--
--
--
--
--
--
--
--
View Specific:
--
--
--
--
--
--
--
--
--
Click here
*In mg/kg body weight per day, unless otherwise specified.


Noncancer Oral Synopsis:

U.S. EPA evaluated the noncancer oral toxicity data for furan, and derived a reference dose (RfD) of 0.001 mg/kg-day.

The biomonitoring equivalent (BE) was derived by Aylward et al. (2010). A BE is the concentration or range of concentrations of a chemical in a biological medium (blood, urine, or other medium) that is consistent with an existing health-based exposure guideline. BE values are most appropriately used as screening values to evaluate biomonitoring data in the context of existing risk assessments rather than for assessing data from individuals. BE values are derived through integration of available data on toxicokinetics with the toxicity data underlying the exposure guidelines (Hays et al. 2008). Values were derived using a previously-published physiologically based pharmacokinetic (PBPK) model (Aylward et al., 2008). Additional important information regarding the derivation, appropriate application, and limitations of BE values in the assessment of biomonitoring data is available in the published derivation (Aylward et al., 2008). Click on the green circle(s) for more information.

Noncancer Oral Specifics:

U.S.EPA

MOREI:
Details on this chemical's assessment are available on U.S. EPA's Integrated Risk Information System (IRIS).

U.S. EPA, 1998. Integrated Risk Information System (IRIS). Online. National Center for Environmental Assessment, Washington, DC. Available at http://www.epa.gov/iris/.

Aylward, L.L., LaKind, J.S., Hays, S.M. 2008. Biomonitoring Equivalents (BE) dossier for trihalomethanes. 2008 Oct;58(1):33-44. PubMed PMID: 18579267.

Aylward L.L., Kirman C.R., Blount B.C., Hays S.M. 2010. Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs) application of steady-state PBPK model solutions. Regul Toxicol Pharmacol. 2010 Oct;58(1):33-44. PubMed PMID: 20685286.

Hays S.M., Aylward L.L., LaKind J.S., Bartels M.J., Barton H.A., Boogaard P.J., Brunk C., DiZio S., Dourson M., Goldstein D.A., Lipscomb J., Kilpatrick M.E., Krewski D., Krishnan K., Nordberg M., Okino M., Tan Y.M., Viau C., Yager J.W. 2008. Guidelines for the derivation of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. 2008 Aug;51(3 Suppl):S4-15. PubMed PMID: 18583008.


Cancer Oral Risk Values Table:

ITER Cancer Oral Risk Table for: FURAN
Risk Value Parameter OrganizationATSDRHealth CanadaIARCIPCSIPRVITER PRNSF IntlRIVMTCEQU.S.EPA
Risk Value Name
--
--
NA
--
--
--
--
--
--
--
Risk Value*
--
--
NA
--
--
--
--
--
--
--
Year
--
--
1995
--
--
--
--
--
--
--
Classification
--
--
2B
--
--
--
--
--
--
--
Target Organ
--
--
NA
--
--
--
--
--
--
--
Species
--
--
NA
--
--
--
--
--
--
--
Study
--
--
NA
--
--
--
--
--
--
--
Biomonitoring Blood
--
--
--
--
--
--
--
--
--
--
Biomonitoring Urine
--
--
--
--
--
--
--
--
--
--
View Specific:
--
--
Click here
--
--
--
--
--
--
--
*In mg/kg body weight per day, unless otherwise specified.


Cancer Oral Synopsis:

IARC evaluated the oral carcinogenicity data for furan, and classified it as possibly carcinogenic to humans (Group 2B), based on inadequate evidence for carcinogenicity in humans and sufficient evidence for carcinogenicity in experimental animals. The IARC evaluation considers the evidence of carcinogenicity in humans and experimental animals, as well as other data relevant to the evaluation of carcinogenicity and its mechanisms. IARC does not generally develop risk values or other estimates of potency.

Cancer Oral Specifics:

IARC

PEER:
Each IARC evaluation is developed by an international working group of experts, which meets to discuss and finalize the monograph text and to formulate the evaluations. Working Group members are chosen on the basis of their knowledge and experience, with due regard given to avoid situations where financial or other interests might affect the outcome of their work. The members of a Working Group are invited to serve in their individual capacities as scientists, and not as representatives of their governments or of any organization with which they are affiliated. Representatives of national and international agencies are also invited to the meetings, and others may attend as observers.

MOREI:
International Agency for Research on Cancer (IARC) Monographs. Dry Cleaning, Some Chlorinated Solvents and Other Industrial Chemicals. 1995. Volume 63, page 404. Summaries &; Evaluations available at http://monographs.iarc.fr/ENG/Monographs/vol63/index.php

Additional information about the IARC Monographs (including ordering information and links to other Monographs) can be found at http://monographs.iarc.fr/


Noncancer Inhalation Risk Values Table:

ITER Noncancer Inhalation Risk Table for: FURAN
Risk Value Parameter OrganizationATSDRHealth CanadaIARCIPCSIPRVITER PRNSF IntlRIVMTCEQU.S.EPA
Risk Value Name
--
--
--
--
--
--
--
--
--
--
Risk Value*
--
--
--
--
--
--
--
--
--
--
Year
--
--
--
--
--
--
--
--
--
--
Base(Experimental)*
--
--
--
--
--
--
--
--
--
--
Basis(Adjusted)*
--
--
--
--
--
--
--
--
--
--
Uncertainty Factor
--
--
--
--
--
--
--
--
--
--
Critical Organ or Effect
--
--
--
--
--
--
--
--
--
--
Species
--
--
--
--
--
--
--
--
--
--
Study
--
--
--
--
--
--
--
--
--
--
Biomonitoring Blood
--
--
--
--
--
--
--
--
--
--
Biomonitoring Urine
--
--
--
--
--
--
--
--
--
--
View Specific:
--
--
--
--
--
--
--
--
--
--
*In mg/kg body weight per day, unless otherwise specified.

Noncancer Inhalation Specifics:


Cancer Inhalation Risk Values Table:

ITER Cancer Inhalation Risk Table for: FURAN
Risk Value Parameter OrganizationATSDRHealth CanadaIARCIPCSIPRVITER PRNSF IntlRIVMTCEQU.S.EPA
Risk Value Name
--
--
NA
--
--
--
--
--
--
--
Risk Value*
--
--
NA
--
--
--
--
--
--
--
Year
--
--
1995
--
--
--
--
--
--
--
Classification
--
--
2B
--
--
--
--
--
--
--
Target Organ
--
--
NA
--
--
--
--
--
--
--
Species
--
--
NA
--
--
--
--
--
--
--
Study
--
--
NA
--
--
--
--
--
--
--
Biomonitoring Blood
--
--
--
--
--
--
--
--
--
--
Biomonitoring Urine
--
--
--
--
--
--
--
--
--
--
View Specific:
--
--
Click here
--
--
--
--
--
--
--
*In mg/kg body weight per day, unless otherwise specified.


Cancer Inhalation Synopsis:

IARC evaluated the inhalation carcinogenicity data for furan, and classified it as possibly carcinogenic to humans (Group 2B), based on inadequate evidence of carcinogenicity in humans and sufficient evidence of carcinogenicity in experimental animals. The IARC evaluation considers the evidence of carcinogenicity in humans and experimental animals, as well as other data relevant to the evaluation of carcinogenicity and its mechanisms. IARC does not generally develop risk values or other estimates of potency.

Cancer Inhalation Specifics:

IARC

PEER:
Each IARC evaluation is developed by an international working group of experts, which meets to discuss and finalize the monograph text and to formulate the evaluations. Working Group members are chosen on the basis of their knowledge and experience, with due regard given to avoid situations where financial or other interests might affect the outcome of their work. The members of a Working Group are invited to serve in their individual capacities as scientists, and not as representatives of their governments or of any organization with which they are affiliated. Representatives of national and international agencies are also invited to the meetings, and others may attend as observers.

MOREI:
International Agency for Research on Cancer (IARC) Monographs. Dry Cleaning, Some Chlorinated Solvents and Other Industrial Chemicals. 1995. Volume 63, page 404. Summaries &; Evaluations available at http://monographs.iarc.fr/ENG/Monographs/vol63/index.php

Additional information about the IARC Monographs (including ordering information and links to other Monographs) can be found at http://monographs.iarc.fr/

NO Revision History: